Pancreatic Enzyme Replacement Therapy: Imports
The question
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 4 March 2025 to Question 35462 on Pancreatic Enzyme Replacement Therapy shortages, if he will publish the volume of unlicensed pancreatic enzyme replacement therapy stock imported since 1 January 2024.
Answered by Karin Smyth
The Department does not hold details on the volume of unlicensed pancreatic enzyme replacement therapy (PERT) stock imported since 1 January 2024. The Department continues to work with specialist importers who have sourced unlicensed stock to assist in covering the remaining gap in the market. The Department, in collaboration with NHS England, has created a webpage to include easily accessible advice on the prescribing and ordering of alternative PERT products, including unlicensed imports where licensed stock is unavailable.
Verbatim has judged this answer against the question that was actually asked — answered, partly answered, or evaded. Sign in to see the verdict →